Investors with significant capital have recently shown a bullish interest in BridgeBio Pharma (BBIO), as evidenced by notable options trading activity. Benzinga’s options scanner identified 14 unusual options trades for BBIO, with a split sentiment of 71% bullish and 21% bearish among big-money traders. These trades included 2 puts totaling $97,005 and 12 calls totaling $785,004, indicating a positive market outlook.
The trading activity suggests that major investors are targeting a price range of $40.0 to $70.0 for BBIO over the recent months. The mean open interest for BBIO options trades stands at 2837.56 with a total volume of 5,906.00, reflecting substantial liquidity and interest in the stock. A 30-day overview of call and put volume within the $40.0 to $70.0 strike price range illustrates the evolving trading patterns surrounding BridgeBio Pharma.
BridgeBio Pharma is a biotech company specializing in developing treatments for genetic diseases, with a focus on Mendelian disorders, oncology, and gene therapy. Notably, one of its key programs, Attruby (acoramidis), aims to treat transthyretin amyloid cardiomyopathy. Analyst predictions indicate an average target price of $71.6 for BBIO, aligning with the positive sentiment observed in recent options trading.
Several analysts have shared their insights on BridgeBio Pharma, with varying recommendations and price targets. These include Citigroup maintaining a Buy rating with a $67 target price, Cantor Fitzgerald downgrading to Overweight with a $95 target, and Jefferies lowering its rating to Buy with a $70 target. Traders are advised to stay informed about BBIO’s options trades and market movements to make educated decisions and manage potential risks effectively.
Key Takeaways:
– Recent options trading activity suggests a bullish sentiment among big-money investors towards BridgeBio Pharma (BBIO), targeting a price range of $40.0 to $70.0.
– BridgeBio Pharma is focused on developing transformative treatments for genetic diseases, with key programs like Attruby addressing transthyretin amyloid cardiomyopathy.
– Analyst predictions indicate an average target price of $71.6 for BBIO, emphasizing positive market outlook.
– To navigate the risks associated with options trading, traders should stay informed, adapt strategies, and monitor market indicators closely.
Read more on benzinga.com